文献速递泌尿男性生殖肿瘤

CDK7抑制通过灭活MED1抑制去势抵抗性前列腺癌

CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.
PubMed 文献 · Cancer Discov · 2019-08-29

该研究探讨了转录辅激活因子MED1与雄激素受体(AR)在AR驱动的去势抵抗性前列腺癌(CRPC)中的分子关联。MED1在T1457位点受CDK7依赖性磷酸化,并在超级增强子位点与AR结合,对AR介导的转录至关重要。CDK7特异性抑制剂THZ1通过阻断AR/MED1全基因组共招募抑制AR依赖性肿瘤生长,并逆转与高磷酸化MED1相关的恩杂鲁胺耐药表型;在体内,THZ1使AR扩增的人CRPC异种移植小鼠模型肿瘤消退。

要点

  • MED1 T1457磷酸化依赖CDK7,是AR转录成瘾的关键脆弱点。
  • THZ1阻断AR/MED1共招募,抑制AR依赖性肿瘤生长。
  • THZ1逆转MED1高磷酸化相关恩杂鲁胺耐药并诱导CRPC消退。

核心结论

  • CDK7抑制选择性靶向MED1介导的AR依赖性致癌转录扩增,是治疗CRPC的潜在新策略。

研究设计与样本

  • 本研究为临床前分子机制与治疗干预研究,采用AR驱动CRPC模型及AR扩增人CRPC异种移植小鼠模型。

主要发现

  • MED1在T1457位点发生CDK7依赖性磷酸化,并在超级增强子位点与AR物理结合,对AR介导转录必需。
  • CDK7特异性抑制剂THZ1通过阻断AR/MED1全基因组共招募抑制AR依赖性肿瘤生长。
  • THZ1逆转高磷酸化MED1相关的恩杂鲁胺耐药表型。
  • 体内THZ1诱导AR扩增人CRPC异种移植小鼠模型肿瘤消退。

临床怎么用

  • CDK7抑制可能作为AR成瘾性CRPC(包括恩杂鲁胺耐药)的潜在治疗方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metastatic castration-resistant prostate cancer (CRPC) is a fatal disease, primarily resulting from the transcriptional addiction driven by androgen receptor (AR). First-line CRPC treatments typically target AR signaling, but are rapidly bypassed, resulting in only a modest survival benefit with antiandrogens. Therapeutic approaches that more effectively block the AR-transcriptional axis are urgently needed. Here, we investigated the molecular mechanism underlying the association between the transcriptional coactivator MED1 and AR as a vulnerability in AR-driven CRPC. MED1 undergoes CDK7-dependent phosphorylation at T1457 and physically engages AR at superenhancer sites, and is essential for AR-mediated transcription. In addition, a CDK7-specific inhibitor, THZ1, blunts AR-dependent neoplastic growth by blocking AR/MED1 corecruitment genome-wide, as well as reverses the hyperphosphorylated MED1-associated enzalutamide-resistant phenotype. In vivo, THZ1 induces tumor regression of AR-amplified human CRPC in a xenograft mouse model. Together, we demonstrate that CDK7 inhibition selectively targets MED1-mediated, AR-dependent oncogenic transcriptional amplification, thus representing a potential new approach for the treatment of CRPC. SIGNIFICANCE: Potent inhibition of AR signaling is critical to treat CRPC. This study uncovers a driver role for CDK7 in regulating AR-mediated transcription through phosphorylation of MED1, thus revealing a therapeutically targetable potential vulnerability in AR-addicted CRPC.See related commentary by Russo et al., p. 1490.This article is highlighted in the In This Issue feature, p. 1469.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Rasool RU, Natesan R, Deng Q, et al. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discov. 2019. PMID: 31466944. doi:10.1158/2159-8290.CD-19-0189

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。